Converted SIY-specific cells in the TdLN were highly enriched for CD44+CD62L− effectors (Fig. 3biii), consistent with the fact that the majority of SIY-specific cells in the tumor are also CD44+CD62L−29. The gene discussed is SELL; the disease is neoplasm.